Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.
Saved in:
| Title: | Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial. |
|---|---|
| Authors: | Capdevila J; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. jcapdevila@vhio.net.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. jcapdevila@vhio.net., Hernando J; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Molina-Cerillo J; Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain., Plana Serrahima M; Medical Oncology Department, Catalan Institute of Oncology (ICO), IDIBELL, ONCOBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Taberna Sanz M; Medical Oncology Department, Catalan Institute of Oncology (ICO), IDIBELL, ONCOBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Castelo B; Medical Oncology Department, University Hospital La Paz, Madrid, Spain., Álvarez-Escolá C; Endocrinology Department, University Hospital La Paz, Madrid, Spain., Carmona-Bayonas A; Medical Oncology Department, Hospital Universitario Morales Meseguer, Universidad de Murcia (UMU), IMIB, Murcia, Spain., Ballester Navarro I; Medical Oncology Department, Hospital Universitario Morales Meseguer, Universidad de Murcia (UMU), IMIB, Murcia, Spain., Iglesias L; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Bover M; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Garcia-Alvarez A; Department of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Lavernia J; Medical Oncology Department, Hospital Fundación IVO (Instituto Valenciano de Oncología), Valencia, Spain., Yayá Tur R; Medical Oncology Department, Hospital Fundación IVO (Instituto Valenciano de Oncología), Valencia, Spain., Ruiz S; UGCI of Medical Oncology, Hospitales Regional y Universitario Virgen de la Victoria, IBIMA, UMA, Málaga, Spain., Baste N; Medical Oncology Department, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain., Lorenzo-Lorenzo I; Medical Oncology Service, Complejo Universitario Hospitalario de Vigo (CHUVI) Alvaro Cunqueiro, Vigo, Pontevedra, Spain., Sanchez-Hernandez A; Medical Oncology Service, Hospital Provincial de Castellón, Castellón de La Plana, Spain., Sanz-Garcia E; Medical Oncology Department, Centro Integral Oncológico 'Clara Campal', Hospital Universitario HM Sanchinarro, Madrid, Spain.; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada., Marquina G; Medical Oncology Department, Hospital Clínico Universitario San Carlos, Department of Medicine, School of Medicine, Universidad Complutense de Madrid (UCM), IdISSC, Madrid, Spain., Nuciforo P; Molecular Oncology Group, Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Elguero B; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Grande E; Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain., Alonso-Gordoa T; Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. |
| Source: | Nature communications [Nat Commun] 2026 Apr 04; Vol. 17 (1). Date of Electronic Publication: 2026 Apr 04. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-026-71155-y |
